Vincristine Sulfate (vincristine sulfate)

A 50% reduction in conventional vincristine dose is recommended for patients with a direct serum bilirubin concentration exceeding 3 mg/dL or other evidence of clinically important hepatic impairment.

The manufacturer makes no specific recommendations regarding dosage of liposomal vincristine in patients with hepatic impairment. (See Pharmacokinetics.)

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

Formal studies of drug interactions have not been conducted for liposomal vincristine; however, liposomal vincristine is expected to interact with drugs known to interact with conventional vincristine.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Vincristine can cause fetal toxicity when administered to pregnant women, but potential benefits from use of the drug may be acceptable in certain conditions despite the possible risks to the fetus. The drug can induce teratogenic and embryocidal effects in animals at doses that are not toxic to the pregnant animal. Dosages of conventional vincristine that caused resorption of 23-85% of fetuses in pregnant mice and hamsters produced fetal malformations that were present in surviving offspring. In 5 monkeys receiving single doses of conventional vincristine between days 27-34 of gestation, 3 fetuses were normal at term, while 2 had grossly evident malformations. Administration of liposomal vincristine to pregnant rats during organogenesis caused teratogenicity (skeletal and visceral malformations), decreased fetal weight, increased embryofetal deaths (resorptions, postimplantation losses), and decreased maternal body weight. Fetal malformations were observed in pregnant rats receiving liposomal vincristine at exposure levels that were approximately 20-40% of the human exposure at the recommended dosage. There are no adequate and controlled studies to date using conventional or liposomal vincristine in pregnant women, and the drugs should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. Women of childbearing potential should be advised to avoid becoming pregnant while receiving conventional or liposomal vincristine. When conventional or liposomal vincristine is administered during pregnancy or the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus.

It is not known whether vincristine or its metabolites are distributed into milk. Because of the potential for serious adverse effects in nursing infants, a decision should be made whether to discontinue nursing or conventional or liposomal vincristine, taking into account the importance of the drug to the woman.

No enhanced messaging available.